期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 61, 期 7, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00486-17
关键词
ceftazidime-avibactam; Klebsiella pneumoniae; resistance; New Delhi metallo-beta-lactamase
资金
- Cleveland Department of Veterans Affairs
- Veterans Affairs Merit Review Program [1I01BX001974]
- Biomedical Laboratory Research & Development Service of the VA Office of Research
- Development and the Geriatric Research Education and Clinical Center [VISN 10]
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI063517, R01AI072219, R01AI100560]
The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance in vitro, ceftazidime-avibactam previously demonstrated in vivo activity against NDM-positive Enterobacteriaceae. Herein, we observed in vitro synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM. In vivo, humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log(10) CFU bacterial reduction; therefore, no in vivo synergy was observed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据